Gelesis has raised $22 million to support an ongoing 6-month trial of its first-generation weight loss capsule, Gelesis100. The company recently started the study to assess its impact on body weight and glycemic control. This data could be sufficient to gain a CE mark, the company expects.
To transport a hunger-suppressing molecule to the gut as a treatment for obesity, researchers at Vanderbilt University have put bacteria to work. The bacteria become lodged in the digestive system and release the lipid for up to a year at a time, altering the gut microbiome to stave off weight-related problems like diabetes and heart disease.
Study: U.S. healthcare reform has led to a diabetes diagnosis surge in states with Medicaid expansion
The enactment of the Affordable Care Act with its expansion of Medicaid benefits has led to an uptick in diabetes diagnoses by almost one-quarter, according to a study of deidentified test results from Quest Diagnostics. That's in states that opted to expand Medicaid under the new law during the first 6 months of 2014 as compared to the first 6 months of 2013.
Baxter International is working to scale up its dialysis product manufacturing because it's been unable to meet demand. In September 2013, Baxter acquired Gambro for $4 billion, which is slated to be part of the core of the new medical products focus for Baxter, while a new company, Baxalta, will hold all the biopharma assets of the current company.
The Mayo Clinic and Gentag are partnering to develop next-generation, wireless, disposable patch sensors to enable researchers to track patient movements in order to better address conditions such as diabetes and obesity.
Pharma watchers have been tracking the launch of MannKind's Afrezza like other people track batting averages or Oscar buzz. Unfortunately for fans of the inhaled insulin, early numbers don't look good. So much so that Goldman Sachs downgraded MannKind's stock and cut its peak sales projection in half.
The FDA is taking action to ensure that multidose insulin pens do not spread diseases by requiring the injectable devices to display the warning "For single patient use only."
Prometheon touts its transdermal delivery system for large molecules, prepares to launch hair growth gel
Prometheon Pharma says it has developed a breakthrough transdermal drug delivery system that can passively deliver large molecules like human growth hormone (which has a size of 2,200 daltons) across the skin.
Survey finds positive correlation between use of digital health tools and health status among diabetics
A survey of 2,000 Americans with diabetes found that those who regularly use digital tools and the Internet to manage their condition reported being in better health than those who do not.
A Sanofi-backed consortium has won clearance to run a virtual diabetes trial in Europe. The regulatory nod reportedly marks the first time European authorities have green-lit a clinical trial with full electronic informed consent.